Newer combination antifungal therapies for invasive aspergillosis

William J. Steinbach, Praveen R. Juvvadi, Jarrod Fortwendel, Luise E. Rogg

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifungals used in various combination approaches have not demonstrated clear improvement over monotherapy. The current classes of drugs targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways, such as cell stress response or cellular signaling, to maximize efficacy. The calcineurin and the Hsp90 pathways are two such untouched arenas in which targeted manipulation may lead to great advances against aspergillosis.

Original languageEnglish (US)
JournalMedical Mycology
Volume49
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 1 2011

Fingerprint

Aspergillosis
aspergillosis
new combination
cell communication
therapeutics
Calcineurin
Drug Delivery Systems
in vitro studies
Cell Wall
cell membranes
stress response
Animal Models
animal models
Cell Membrane
cell walls
drugs
Therapeutics
cells
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • veterinary(all)
  • Infectious Diseases

Cite this

Newer combination antifungal therapies for invasive aspergillosis. / Steinbach, William J.; Juvvadi, Praveen R.; Fortwendel, Jarrod; Rogg, Luise E.

In: Medical Mycology, Vol. 49, No. SUPPL. 1, 01.04.2011.

Research output: Contribution to journalArticle

Steinbach, William J. ; Juvvadi, Praveen R. ; Fortwendel, Jarrod ; Rogg, Luise E. / Newer combination antifungal therapies for invasive aspergillosis. In: Medical Mycology. 2011 ; Vol. 49, No. SUPPL. 1.
@article{2643d034e2b549ff948643f2e39ba586,
title = "Newer combination antifungal therapies for invasive aspergillosis",
abstract = "Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifungals used in various combination approaches have not demonstrated clear improvement over monotherapy. The current classes of drugs targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways, such as cell stress response or cellular signaling, to maximize efficacy. The calcineurin and the Hsp90 pathways are two such untouched arenas in which targeted manipulation may lead to great advances against aspergillosis.",
author = "Steinbach, {William J.} and Juvvadi, {Praveen R.} and Jarrod Fortwendel and Rogg, {Luise E.}",
year = "2011",
month = "4",
day = "1",
doi = "10.3109/13693786.2010.499374",
language = "English (US)",
volume = "49",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Newer combination antifungal therapies for invasive aspergillosis

AU - Steinbach, William J.

AU - Juvvadi, Praveen R.

AU - Fortwendel, Jarrod

AU - Rogg, Luise E.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifungals used in various combination approaches have not demonstrated clear improvement over monotherapy. The current classes of drugs targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways, such as cell stress response or cellular signaling, to maximize efficacy. The calcineurin and the Hsp90 pathways are two such untouched arenas in which targeted manipulation may lead to great advances against aspergillosis.

AB - Optimal therapy for invasive aspergillosis is unknown, and many clinicians have attempted to utilize a combination antifungal approach to improve outcomes. However, while numerous in vitro studies, animal models, and clinical reports suggest the possibility that combination antifungal therapy might offer improved results, there is no definitive accepted strategy. The currently available antifungals used in various combination approaches have not demonstrated clear improvement over monotherapy. The current classes of drugs targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways, such as cell stress response or cellular signaling, to maximize efficacy. The calcineurin and the Hsp90 pathways are two such untouched arenas in which targeted manipulation may lead to great advances against aspergillosis.

UR - http://www.scopus.com/inward/record.url?scp=79952645830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952645830&partnerID=8YFLogxK

U2 - 10.3109/13693786.2010.499374

DO - 10.3109/13693786.2010.499374

M3 - Article

VL - 49

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - SUPPL. 1

ER -